Luisa Villa

Dr. Luisa Villa


Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2005 in The Lancet Oncology
Verified
Journal Article
Closed access
LVLuisa Villa
Luisa Villa
RCRonaldo Lr Costa
Ronaldo Lr Costa
CPCarlos A Petta
Carlos A Petta
RARosires P Andrade
Rosires P Andrade
KAKevin A Ault
Kevin A Ault
EBEliav Barr
Eliav Barr

21 November 2006 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
LVLuisa Villa
Luisa Villa
RCR L R Costa
R L R Costa
CPC A Petta
C A Petta
RAR P Andrade
R P Andrade
JPJorma Paavonen
Jorma Paavonen
EBE Barr
E Barr
Human papillomavirus (HPV) causes cervical, vulvar, and vaginal cancers, precancerous dysplasia, and genital warts. We report data for the longest efficacy evaluation to date of a prophylactic HPV vaccine. In total, 552 women (16–23 years) were enrolled in a randomised, placebo-controlled study of a quadrivalent HPV 6/11/16/18 L1 virus-like-particle vaccine with vaccination at months 0, 2, and 6. At regular intervals through 3 years, subjects underwent gynaecologic examination, cervicovaginal sampling for HPV DNA, serum anti-HPV testing, and Pap testing, with follow-up biopsy as indicated. A subset of 241 subjects underwent two further years of follow-up. At 5 years post enrolment, the combined incidence of HPV 6/11/16/18-related persistent infection or disease was reduced in vaccine-recipients by 96% (two cases vaccine versus 46 placebo). There were no cases of HPV 6/11/16/18-related precancerous cervical dysplasia or genital warts in vaccine recipients, and six cases in placebo recipients (efficacy=100%; 95% CI:12–100%). Through 5 years, vaccine-induced anti-HPV geometric mean titres remained at or above those following natural infection. In conclusion, a prophylactic quadrivalent HPV vaccine was effective through 5 years for prevention of persistent infection and disease caused by HPV 6/11/16/18. This duration supports vaccination of adolescents and young adults, which is expected to greatly reduce the burden of cervical and genital cancers, precancerous dysplasia, and genital warts.

1 July 2006 in Vaccine
Verified
Journal Article
Closed access
LVLuisa Villa
Luisa Villa
KAKevin A. Ault
Kevin A. Ault
AGAnna R. Giuliano
Anna R. Giuliano
RCRonaldo L.R. Costa
Ronaldo L.R. Costa
CPCarlos A. Petta
Carlos A. Petta
EBEliav Barr
Eliav Barr

21 February 2007 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
LSLaura Sichero
Laura Sichero
SFSilvaneide Ferreira
Silvaneide Ferreira
HTHelen Trottier
Helen Trottier
EDEliane Duarte‐Franco
Eliane Duarte‐Franco
AFAlex Ferenczy
Alex Ferenczy
LVLuisa Villa
Luisa Villa
The intratypic variability of HPVs 16 and 18 has been extensively studied and has been used as an important tool in epidemiological studies of viral transmission, persistence and progression to clinically relevant cervical lesions. Infections by non‐European variants of HPVs 16 and 18 are associated with an increased risk for the development of high grade squamous intraepithelial lesions (HSIL). Our aim was to correlate the intratypic molecular variability of both HPV types and risk of persistent infection and lesion outcome in a cohort study conducted in Brazil. We characterized molecular variants of HPV types 16 and 18 by sequencing a fragment of the LCR, and of the E6 and L1 genes, for HPV‐16 variants only. For both types, European variants composed the most prevalent and diverse group. Persistent infections with HPV‐18 were associated with continuous detection of European variants. However, risk for simultaneous detection of HSIL and HPV DNA was higher in women harboring non‐European variants of HPV‐16. The same trend was observed with HSIL detected during follow‐up. Our study confirms the association between non‐European variants and risk of cervical neoplasia, and highlights the importance of their geographic distribution for cervical cancer risk assessment.

18 March 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
EWEliana Wendland
Eliana Wendland
LVLuisa Villa
Luisa Villa
EUElizabeth Robinson Unger
Elizabeth Robinson Unger
CDCarla Magda Domingues
Carla Magda Domingues
ABAdele Schwartz Benzaken
Adele Schwartz Benzaken
FMFlavia Moreno
Flavia Moreno
For Brazil, there are no nationwide data on HPV prevalence against which the impact of the HPV immunization program can be measured in the future. Therefore, we aim to evaluate the prevalence of genital HPV infection among adolescents and young adults in Brazil. A cross-sectional, multicentric, nationwide survey was conducted between September 2016 and November 2017. Sexually active unvaccinated women and men aged 16 to 25 years old were recruited from 119 public primary care units, including all 26 state capitals and the Federal District. All participants answered a face-to-face interview and provided biological samples for genital HPV analysis. We used an automated DNA extraction method and HPV genotyping was performed using the Linear Array genotyping test (Roche). Of 7,694 participants, 53.6% (95% CI 51.4–55.8) were positive for any HPV type. The prevalence of high-risk HPV types was significantly higher in women (38.6% vs. 29.2%, P < 0·001). The HPV types included in the quadrivalent vaccine were detected in 1002 (14.8%) specimens, with a different pattern of HPV infection between sexes. Characteristics associated with overall HPV detection included female gender, self-declaration of race as brown/pardo, lower socioeconomic class, single or dating, current smoking and having 2 or more sex partners in the past year. We found a high prevalence of HPV, with significant differences between regions. Our data provide information that may be considered when developing HPV prevention policies and constitute a baseline against which the impact of the HPV immunization program in Brazil can be measured in future years.